PatientsVille.com Logo


Migraine Medical Research Studies

Up-to-date List of Migraine Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Migraine Medical Research Studies

Rank Status Study
1 Recruiting MIBRAIN - Migraine and the Brain: Consequences, Causes, and Vascular Interaction
Condition: Migraine
Interventions: Device: MRI;   Device: EndoPAT;   Other: Neuropsychological battery
Outcome Measures: Differences in magnetic resonance imaging (MRI) between Migraine without aura and Migraine with aura patients (frequency of hyperintensities, white matter lesions....);   Differences in the Total Score of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) between Migraine without aura and Migraine with aura patients.;   Differences in the Reactive Hyperemia Index (RHI) and the Augmentation Index (AI) between Migraine without aura and Migraine with aura patients;   Correlation between MRI and Total Score of RBANS with RHI / AI (endothelial function) between Migraine groups.
2 Recruiting Behavioral Weight Loss as a Treatment for Migraine in Obese Women
Conditions: Migraine;   Obesity
Interventions: Behavioral: Behavioral Weight Loss Intervention;   Other: Migraine Education
Outcome Measures: Change in the number of Migraine headache days;   Change in body weight;   Changes in serum inflammatory markers (C-reactive protein, Interleukin-6);   Changes in depression;   Changes in physical activity;   Changes in fat intake and other diet/eating behavior components
3 Recruiting One-Day Intervention for Depression and Impairment in Migraine Patients
Conditions: Migraine;   Depression
Interventions: Behavioral: ACT-ME;   Behavioral: Migraine Education Only
Outcome Measures: HRSD;   SCID-IV;   WHO-DAS-II;   WHO-QOL;   HDI
4 Unknown  Identification of Inflammatory Markers in Migraine Patients
Conditions: Inflammation;   Migraine;   Headache
Outcome Measures: To evaluate if the levels of inflammatory markers in patients with Migraine is higher compared to the levels of these markers in the control groups.;   To evaluate the levels of inflammatory markers in-between Migraine and other forms of headaches.
5 Recruiting Migraine and Body Composition
Conditions: Migraine With and Without Aura;   Chronic Migraine;   Healthy Controls
Outcome Measures: association between Migraine and obesity - evaluate serum adipokine levels;   association between Migraine and obesity -evaluate subcutaneous adipose tissue (SAT) and its ratio to visceral adipose tissue (VAT)
6 Unknown  Influence of a Dietary Supplement as Treatment of Migraine in Children and Adolescents
Condition: Migraine
Intervention: Dietary Supplement: Migra 3
Outcome Measures: number of days with headache before and after 12 weeks of daily treatment with a Migraine specific dietary supplement;   frequency, duration and intensity of the Migraine
7 Unknown  Treximet in Acute Migraine Headache: Assessing Cognitive Function
Conditions: Migraine Headache;   Cognitive Impairment
Interventions: Drug: Treximet;   Drug: Migraine rescue medication of choice
Outcome Measures: To evaluate the effectiveness of treatment with Treximet versus placebo in patients with acute Migraine headache on the neuropsychological function before treatment and at one and two hours after treatment of a Migraine.;   To assess incidence and types of neuropsychological deficits by MEWT in patients with acute Migraine headache before treatment.
8 Recruiting The Childhood and Adolescent Migraine Prevention Study
Conditions: Migraine;   Migraine Disorders;   Headache
Interventions: Drug: Amitriptyline;   Drug: Topiramate;   Drug: Placebo
Outcome Measures: Reduction in Migraine Frequency (amitriptyline and topiramate);   Reduction in absolute Migraine disability score on PedMIDAS;   Safety and tolerability of amitriptyline and topiramate;   Occurrence of treatment-emergent serious adverse events;   Reduction in absolute Migraine frequency days
9 Recruiting Acupuncture for Migraine Prophylaxis
Conditions: Migraine Without Aura;   Unilateral Headache
Intervention: Other: acupuncture
Outcome Measures: frequency of Migraine attacks;   headache severity
10 Recruiting A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache
Condition: Migraine Headache, Episodic
Intervention: Device: neuromodulation for episodic Migraine headache
Outcome Measures: Number of monthly Migraine headache days;   Number of monthly Migraine headache days (reduction by by 50% or more);   Total monthly pain score;   Mood and cognition measures - Change in mood scores;   Verify the absence of material dizziness;   Mood and cognition measures - Change in cognitive speed scores;   Mood and cognition measures - Change in memory scores
11 Not yet recruiting Prediction of Migraine Prevention Efficacy: Individualization of Treatment by Coupling Drug's Mode of Action With Patient's Mechanism of Pain Modulation
Conditions: Migraine;   Preventive Treatment
Interventions: Drug: Amitriptyline;   Drug: placebo
Outcome Measures: the association between pre-treatment assessment parameter(s) and the reduction in frequency of Migraine attacks by amitriptyline;   the association between pain-related psychological parameters and the reduction in Migraine attacks by amitriptyline
12 Recruiting A Randomized, Parallel, Double-blind, Placebo-controlled Study of Vitamin D as Prophylactic Treatment for Migraine
Condition: Migraine According to International Headache Society (IHS) Criteria (ICHD-II)
Interventions: Drug: D3 Vitamin ®;   Drug: Placebo
Outcome Measures: The number of Migraine attacks;   Evaluation of pain during Migraine attacks;   Hypersensitivity;   Migraine Symptoms;   Quantitative Sensory Testing;   Measuring levels of a biomarker. Changes in the levels of these biomarkers.
13 Recruiting Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?
Condition: Workplace Migraine Treatment
Interventions: Drug: Usual prescribed triptan;   Drug: Treximet for Migraine treatment
Outcome Measures: workplace productivity compared between Migraines treated with usual triptan versus Migraines treated with Treximet;   comparison of patient completeness of response to Migraine treatments across 6 treated workplace Migraines
14 Recruiting TI-001 (Intranasal Oxytocin) for Treatment of Chronic Migraine
Condition: Chronic Migraine
Interventions: Drug: TI-001;   Drug: Placebo
Outcome Measures: Mean reduction in Migraine headache days;   Change in Migraine pain scores measured with a 4-point verbal rating scale;   Frequency of nausea;   Frequency of photophobia;   Frequency of phonophobia;   Frequency of Migraine episodes;   Time to study discontinuation due to any cause;   Frequency and severity of adverse events
15 Recruiting Pathway M-1: Sphenopalatine Ganglion Stimulation for the Treatment of Chronic or High Frequency, High Disability Migraine Headache
Conditions: Chronic Migraine;   High Frequency, High Disability Migraine
Intervention: Device: ATI Neurostimulation System
Outcome Measures: Major Device- and Surgical-Related Complications;   Effective Therapy;   Headache Frequency;   Pain Relief at 1 Hour;   Pain Freedom at 1 Hour;   Migraine Associated Symptom Relief at 1 Hour;   Disability and Quality of Life;   Global Evaluation of SPG Stimulation Therapy;   Prophylactic Medication Use;   Acute Medication Use
16 Unknown  Inflammatory Markers Identification in Migraine Patients
Conditions: Inflammation;   Migraine;   Headache
Outcome Measure:
17 Unknown  The Efficacy and Safety of Intra-oral Topical Ketoprofen for the Treatment of Acute Migraine
Conditions: Migraine Disorders;   Migraine Headache;   Migraine;   Acute Migraine
Interventions: Drug: Topical, intra-oral ketoprofen gel;   Other: Placebo gel
Outcome Measures: Pain relief (defined as at least 2 graded reduction in a 5-grade scale) at 120 minutes post-treatment;   Pain free status at 30, 60, 120, and 240 minutes post-treatment based on headache severities reported in patient's journals;   Pain relief at 30, 60, and 240 minutes post-treatment based on headache severities reported in patient's journals;   Relief of Photophobia at 30, 60, 120, and 240 minutes post-treatment;   Relief of Phonophobia at 30, 60, 120, and 240 minutes post-treatment;   Relief of Nausea at 30, 60, 120 and 240 minutes post-treatment;   Relief of Vomiting 30, 60, 120 and 240 minutes post-treatment;   Need for Rescue Medication between the time of dosing to 240 minutes
18 Recruiting PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load
Condition: Migraine Without Aura
Intervention: Drug: PACAP
Outcome Measures: PACAP induced Migraine attacks in patients with high and low genetic load.;   PACAP induced Migraine attacks in patients with high and low genetic load
19 Recruiting Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects
Condition: Migraine
Intervention: Drug: Clopidogrel
Outcome Measures: Mean number of monthly Migraine days per patient within the 3 months following transcatheter ASD closure.;   Severity of Migraine attacks following ASD closure as evaluated by the intensity of Migraine episodes and the Migraine Disability Assessment (MIDAS) questionnaire at 3-month follow-up after ASD closure.;   Incidence of bleeding complications at 3-month follow-up.;   Percentage of patients with new-onset Migraine attacks.;   Time to first Migraine episode.;   Percentage of patients with Migraine headaches at 6-month and 1-year follow-up (exploratory only according to local feasibility).
20 Recruiting A Randomized, Placebo-Controlled, Double-blind Study of Tianshu Capsule in the Treatment of Migraine.
Condition: Migraine
Interventions: Drug: Tianshu capsule;   Drug: Sugar pill
Outcome Measures: Change in the frequency of attack of Migraine Per 4 weeks at Week 16 from baseline;   Change in seizure duration of Migraine Per 4 weeks at Week 16 from baseline.;   Change in degree of pain of Migraine Per 4 weeks at Week 16 from baseline.;   Change in the days using acute therapy of Migraine Per 4 weeks at Week 16 from baseline.;   Proportion of subjects whose number or days of Migraine attacks reduce at least 50%.;   Change in number of concomitant migrainous symptoms attacks Per 4 weeks at Week 16 from baseline.;   Safety assessments will be based on adverse event reports and the results of vital sign measurements, electrocardiogram, and clinical laboratory tests.

These studies may lead to new treatments and are adding insight into Migraine etiology and treatment.

A major focus of Migraine research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Migraine